Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophy.

Nat Commun · 2019 · PMC6594976 · PMID 31243277

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

a strong trendP = 0.06so close (0.05 < p ≤ 0.1)

QPCR assays showed reduced expression of Ccr2 and its ligands Ccl2 , Ccl8 and Ccl12 in muscles of CD11b/LIF BMT recipients, and a strong trend for lower levels of Ccl7 expression ( P = 0.06) (Fig. 4a ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.